Lasofoxifene and abemaciclib breast cancer trial

Study overview

California Research Institute lists an open-label, randomized, multicenter breast cancer study comparing lasofoxifene with abemaciclib against fulvestrant with abemaciclib. The study is intended for premenopausal and postmenopausal women and men with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer that has an ESR1 mutation. Current local availability and the complete protocol criteria must be confirmed with the research team.

What the research compares

Randomization assigns participants to a study group according to the protocol rather than choice. One group receives lasofoxifene with abemaciclib, while the comparison group receives fulvestrant with abemaciclib. Because the study is open-label, participants and investigators know which assigned treatment is given. A multicenter design means participating research sites follow the same study plan. The research evaluates the efficacy and safety of the two combinations in the defined population; this page does not predict an individual result.

Asking about participation

A research coordinator can explain whether the study is accepting inquiries, outline screening, and review the official eligibility requirements. Screening may include confirmation of diagnosis, disease characteristics, prior treatment information, and other protocol-defined assessments. Only the study team can determine eligibility after reviewing the protocol and medical information through a secure process.

Contacting the institute does not enroll you or replace guidance from your oncology team. Participation is voluntary. Before enrollment, the informed-consent process reviews study procedures, potential risks, possible benefits, alternatives, privacy protections, and your right to stop participation.

Please do not email medical records or sensitive health information. Call (323) 660-6200 or email trials@caresinst.org to request secure next steps.

View all clinical trials